NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗體藥物偶聯物 (ADC) 市場趨勢、市場份額和市場規模預測(2021-2028 年):應用(血液癌/乳腺癌)、技術(可切割接頭/無接頭),按地區劃分

Antibody Drug Conjugate Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Cleavable Linker, Linkerless), By Region, And Segment Forecasts, 2021 - 2028

出版商 Grand View Research, Inc. 商品編碼 1026786
出版日期 內容資訊 英文 125 Pages
商品交期: 2-10個工作天內
價格
抗體藥物偶聯物 (ADC) 市場趨勢、市場份額和市場規模預測(2021-2028 年):應用(血液癌/乳腺癌)、技術(可切割接頭/無接頭),按地區劃分 Antibody Drug Conjugate Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Cleavable Linker, Linkerless), By Region, And Segment Forecasts, 2021 - 2028
出版日期: 2021年08月24日內容資訊: 英文 125 Pages
簡介

全球抗體藥物偶聯物 (ADC) 市場預計在預測期內以 23.7% 的複合年增長率增長,到 2028 年將增長至 239 億美元。

研發投入增加和連接器技術進步等因素正在推動市場增長。

本報告調查了全球抗體藥物偶聯物 (ADC) 市場,定義和概述了市場,分析了影響市場增長的各種影響因素,市場規模的變化/預測,以及用途/技術/區域。/按各種類別細分如主要國家、競爭環境、市場份額、主要公司概況等。

第一章調查方法/範圍

第 2 章執行摘要

第 3 章市場可變因素/趨勢/前景

  • 市場可變因素分析
  • 增長因素影響分析
  • 市場限制
  • 傳播/增長前景映射
  • SWOT 分析
  • 波特五力分析

第 4 章市場分析/預測:按應用

  • 血癌
  • 乳腺癌
  • 尿路上皮癌/膀胱癌
  • 其他

第 5 章市場分析/預測:按技術

  • 可切割的鏈接器
  • 不可切割的接頭
  • 無鏈接器

第 6 章市場分析/預測:按地區/主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章競爭形勢

  • 重大交易及戰略聯盟分析
  • 供應商情況
  • 上市公司
  • 私人公司

第八章公司簡介

  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Astrazeneca
  • Gilead Sciences, Inc.
  • Astellas Pharma
  • Seagen, Inc.
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline Plc
  • ADC Therapeutics
目錄
Product Code: GVR-2-68038-741-4

Antibody Drug Conjugate Market Growth & Trends:

The global antibody drug conjugate market size is expected to reach USD 23.9 billion by 2028, according to a new report by Grand View Research Inc. The market is expected to grow at a CAGR of 23.7% from 2021 to 2028. Increasing investment in R&D and advancements in linker technology are expected to boost the growth of the antibody drug conjugates (ADCs) market.

Antibody-drug conjugates are a novel category of drugs composed of an antibody linked to a cytotoxic drug with a linker. Conventional chemotherapy is intended to kill fast-growing tumor cells. However, it can also damage healthy proliferating cells, which may produce undesirable effects. In contrast, ADCs are designed to increase the efficacy of treatment and decrease the systemic toxicity of chemotherapy drugs. Major players are entering into partnerships for the development & commercialization of these products. For instance, in July 2020, AstraZeneca collaborated with Daiichi Sankyo to develop and commercialize its new ADC candidate, DS-1062, which is in phase 1 trials for triple-negative breast cancer and Non-Small Cell Lung Cancer (NSCLC).

One of the major factors responsible for the growth of the ADCs market is the rising incidence and prevalence of cancer coupled with the growing geriatric population. According to the Cancer Research U.K., during 2015-2017, on average, nearly 36% of new cases were reported among people aged 75 years & above, each year. It is further estimated that by 2035, almost 46% of all cancer cases will be among people in the age group of 75 years & above. Moreover, the rise in the prevalence of cancer in emerging countries further boosts growth. According to Globocan, in 2020, approximately 49.2% of global cancer cases were registered in Asia. Thus, this region remains a major untapped market for ADCs.

ADCs manufacturing is a complicated and expensive process, which requires high capital investment and trained operators, stringent GMP, and high operational difficulties. Challenges in downstream processing of ADCs might restrict the market growth. These include handling MAb-linker-drug binding chemistries, balancing & combining optimal MAb specificity, preventing premature toxin release, and controlling the release of intracellular toxin. Furthermore, the lack of availability of reimbursement policies in developing economies is expected to restrict market growth.

Mergers and acquisitions are one of the key strategies employed by key players to increase their market share. For instance, in December 2020, Boehringer Ingelheim acquired NBE-Therapeutics for USD 1.44 billion. NBE-Therapeutics' expertise in proprietary platforms for ADC development is expected to help Boehringer Ingelheim in the development of ADC drugs.

Antibody Drug Conjugate Market Report Highlights:

  • Breast cancer was the largest revenue-generating segment in 2020 due to a high number of approved ADC products, approval of Kadcyla for early-stage breast cancer, and a high target patient population
  • The cleavable linker segment dominated the market in 2020 due to its wide adoption in ADC's product development
  • Most of the pipeline and commercially available ADCs are based on cleavable linker technology
  • Asia Pacific is expected to witness the fastest CAGR over the forecast period
  • This growth can be credited to the increasing investments in R&D by local players and the rising geriatric population in the region

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
  • 1.12 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Industry Outlook

  • 3.1 Market Variable Analysis
  • 3.2 Driver Impact Analysis
    • 3.2.1 Presence of Strong Product Pipeline
    • 3.2.2 Growing Geriatric Population Base
    • 3.2.3 Increasing Incidence and Prevalence of Cancer
  • 3.3 Market Restraint Analysis
    • 3.3.1 High Manufacturing Cost of Antibody-Drug Conjugates and Challenges in Downstream Processing Of ADCs
    • 3.3.2 Stringent Reimbursement Policies for ADCs
  • 3.4 Penetration and Growth Prospect Mapping
  • 3.5 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
  • 3.6 Porter's Five Forces Analysis

Chapter 4 Application Business Analysis

  • 4.1 Antibody-Drug Conjugates Market: Application Movement Analysis
  • 4.2 Blood Cancer
    • 4.2.1 Blood Cancer Market Estimates And Forecast, 2017 - 2028
    • 4.2.2 Leukemia
      • 4.2.2.1 Leukemia Market Estimates And Forecast, 2017 - 2028
    • 4.2.3 Multiple Myeloma
      • 4.2.3.1 Multiple Myeloma Market Estimates And Forecast, 2017 - 2028
    • 4.2.4 Lymphoma
      • 4.2.4.1 Lymphoma Market Estimates And Forecast, 2017 - 2028
  • 4.3 Breast Cancer
    • 4.3.1 Breast Cancer Market Estimates And Forecast, 2017 - 2028
  • 4.4 Urothelial Cancer & Bladder Cancer
    • 4.4.1 Urothelial Cancer & Bladder Cancer Market Estimates And Forecast, 2017 - 2028
  • 4.5 Others
    • 4.5.1 Others Market Estimates And Forecast, 2017 - 2028

Chapter 5 Technology Business Analysis

  • 5.1 Antibody-Drug Conjugates Market: Technology Movement Analysis
  • 5.2 Cleavable Linker
    • 5.2.1 Cleavable Linker Market Estimates And Forecast, 2017 - 2028
  • 5.3 Non-cleavable Linker
    • 5.3.1 Non-Cleavable Linker Market Estimates And Forecast, 2017 - 2028
  • 5.4 Linkerless
    • 5.4.1 Linkerless Market Estimates And Forecast, 2017 - 2028

Chapter 6 Regional Business Analysis

  • 6.1 Antibody-Drug Conjugates Market: Regional Movement Analysis
  • 6.2 North America
    • 6.2.1 North America Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.2.2 The U.S.
      • 6.2.2.1 The U.S. market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.3.2 The U.K.
      • 6.3.2.1 The U.K. market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.4 Italy
      • 6.3.4.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.5 Spain
      • 6.3.5.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.6 France
      • 6.3.6.1 France market estimates and forecast, 2017 - 2028 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Japan Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 China Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 India Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.4.5 Australia
      • 6.4.5.1 Australia Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.4.6 South Korea
      • 6.4.6.1 South Korea Market Estimates And Forecast, 2017 - 2028 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Mexico Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.5.4 Argentina
      • 6.5.4.1 Argentina Market Estimates And Forecast, 2017 - 2028 (USD Million)
  • 6.6 Middle East & Africa
    • 6.6.1 Middle-East And Africa Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.6.3 Saudi Arabia
      • 6.6.3.1 Saudi Arabia Market Estimates And Forecast, 2017 - 2028 (USD Million)
    • 6.6.4 UAE
      • 6.6.4.1 UAE Market Estimates And Forecast, 2017 - 2028 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Major deals & strategic alliances analysis
    • 7.1.1 New product launch
    • 7.1.2 Mergers and acquisitions
    • 7.1.3 Expansion
    • 7.1.4 Partnerships
  • 7.2 Vendor Landscape
    • 7.2.1 List Of Key Distributors And Channel Partners
    • 7.2.2 Key Company Market Share Analysis, 2020
  • 7.3 Public Companies
    • 7.3.1 Company Market Position Analysis
    • 7.3.2 Competitive Dashboard Analysis
  • 7.4 Private Companies
    • 7.4.1 List Of Key Emerging Companies/Technology Disruptors/ Innovators

Chapter 8 Company Profiles

  • 8.1 Takeda Pharmaceutical Company Limited
    • 8.1.1 Company Overview
    • 8.1.2 Financial Performance
    • 8.1.3 Product Benchmarking
    • 8.1.4 Strategic Initiatives
  • 8.2 F. Hoffmann-La Roche Ltd.
    • 8.2.1 Company Overview
    • 8.2.2 Financial Performance
    • 8.2.3 Product Benchmarking
    • 8.2.4 Strategic Initiatives
  • 8.3 Pfizer, Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Financial Performance
    • 8.3.3 Product Benchmarking
    • 8.3.4 Strategic Initiatives
  • 8.4 Astrazeneca
    • 8.4.1 Company Overview
    • 8.4.2 Financial Performance
    • 8.4.3 Product Benchmarking
    • 8.4.4 Strategic Initiatives
  • 8.5 Gilead Sciences, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Performance
    • 8.5.3 Product Benchmarking
    • 8.5.4 Strategic Initiatives
  • 8.6 Astellas Pharma
    • 8.6.1 Company Overview
    • 8.6.2 Financial Performance
    • 8.6.3 Product Benchmarking
    • 8.6.4 Strategic Initiatives
  • 8.7 Seagen, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Performance
    • 8.7.3 Product Benchmarking
    • 8.7.4 Strategic Initiatives
  • 8.8 Daiichi Sankyo Company, Limited
    • 8.8.1 Company Overview
    • 8.8.2 Financial Performance
    • 8.8.3 Product Benchmarking
    • 8.8.4 Strategic Initiatives
  • 8.9 GlaxoSmithKline Plc
    • 8.9.1 Company Overview
    • 8.9.2 Financial Performance
    • 8.9.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives
  • 8.10 ADC Therapeutics
    • 8.10.1 Company Overview
    • 8.10.2 Financial Performance
    • 8.10.3 Product Benchmarking
    • 8.10.4 Strategic Initiatives

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 North America antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 4 North America antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 5 The U.S. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 6 The U.S. antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 7 Canada antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 8 Canada antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 9 Europe antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 10 Europe antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 11 The U.K. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 12 The U.K. antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 13 Germany antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 14 Germany antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 15 France antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 16 France antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 17 Italy antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 18 Italy antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 19 Spain antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 20 Spain antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 21 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 22 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 23 Japan antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 24 Japan antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 25 China antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 26 China antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 27 India antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 28 India antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 29 Australia antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 30 Australia antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 31 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 32 South Korea antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 33 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 34 Latin America antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 35 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 36 Brazil antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 37 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 38 Mexico antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 39 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 40 Argentina antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 41 MEA antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 42 MEA antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 43 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 44 South Africa antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 45 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 46 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 47 UAE antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 48 UAE antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 49 List of key distributors
  • TABLE 50 List of key emerging companies/technology disruptors/innovators

List of Figures

  • Fig. 1 Antibody-drug conjugates market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Antibody-drug conjugates market snapshot
  • Fig. 10 Antibody-drug conjugates market driver impact
  • Fig. 11 Global population by age group, 2016, 2020, & 2027
  • Fig. 12 Global cancer cases projection,2020-2030 (Number of newly registered cases)
  • Fig. 13 Antibody-drug conjugates market restraint impact
  • Fig. 14 Penetration and growth prospect mapping
  • Fig. 15 SWOT analysis, by factor (political & legal economic and technological)
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 Antibody-drug conjugates market: Application outlook and key takeaways
  • Fig. 18 Antibody-drug conjugates market: Application movement analysis
  • Fig. 19 Blood cancer market estimates and forecasts, 2017 - 2028
  • Fig. 20 Leukemia market estimates and forecasts, 2017 - 2028
  • Fig. 21 Multiple Myeloma market estimates and forecasts, 2017 - 2028
  • Fig. 22 Lymphoma market estimates and forecasts, 2017 - 2028
  • Fig. 23 Breast cancer market estimates and forecasts, 2017 - 2028
  • Fig. 24 Urothelial cancer market estimates and forecasts, 2017 - 2028
  • Fig. 25 Others market estimates and forecasts, 2017 - 2028
  • Fig. 26 Antibody-drug conjugates market: Technology outlook and key takeaways
  • Fig. 27 Antibody-drug conjugates market: Technology movement analysis
  • Fig. 28 Cleavable linker market estimates and forecasts, 2017 - 2028
  • Fig. 29 Non-cleavable linker market estimates and forecasts, 2017 - 2028
  • Fig. 30 Linkerless market estimates and forecasts, 2017 - 2028
  • Fig. 31 Antibody-drug conjugates market: Regional outlook and key takeaways
  • Fig. 32 Antibody-drug conjugates market: Regional movement analysis
  • Fig. 33 North America
  • Fig. 34 North America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 35 The U.S.
  • Fig. 36 The U.S. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 37 Canada
  • Fig. 38 Canada market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 39 Europe
  • Fig. 40 Europe market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 41 The U.K.
  • Fig. 42 The U.K. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 43 Germany
  • Fig. 44 Germany market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 45 Italy
  • Fig. 46 Italy market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 47 Spain
  • Fig. 48 Spain market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 49 France
  • Fig. 50 France market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 51 Asia Pacific
  • Fig. 52 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 53 Japan
  • Fig. 54 Japan market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 55 China
  • Fig. 56 China market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 57 India
  • Fig. 58 India market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 59 Australia
  • Fig. 60 Australia market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 61 South Korea
  • Fig. 62 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 63 Latin America
  • Fig. 64 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 65 Brazil
  • Fig. 66 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 67 Mexico
  • Fig. 68 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 69 Argentina
  • Fig. 70 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 71 Middle East & Africa
  • Fig. 72 Middle East and Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 73 South Africa
  • Fig. 74 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 75 Saudi Arabia
  • Fig. 76 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 77 UAE
  • Fig. 78 UAE market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 79 Company market share analysis
  • Fig. 80 Company market position analysis (Revenue US$ mn)
  • Fig. 81 Company market position analysis (Profit Margin)
  • Fig. 82 Competitive dashboard analysis
  • Fig. 83 Regional Network Map